Scilex Holding Company Announces Dream Bowl I Meme Coin Tokens Commence Trading on the Biconomy Exchange on July 6, 2026
Rhea-AI Summary
Scilex Holding (Nasdaq:SCLX) announced that Dream Bowl I Meme Coin tokens begin trading on the Biconomy Exchange on July 6, 2026. Scilex believes trading may enhance liquidity and distribution for stockholders and other eligible equityholders. The company retains approximately 180 million Dream Bowl Tokens after prior distributions.
Biconomy reports serving over 10 million users in 180+ countries, ranking among the top 40 exchanges by volume with about $2.0 billion in average daily trading, and holding 98% of assets in cold storage.
Positive
- Dream Bowl I Meme Coin tokens start trading on Biconomy on July 6, 2026
- Scilex retains approximately 180 million Dream Bowl Tokens after distributions
- Biconomy averages about $2.0 billion in daily trading volume
- Biconomy reports more than 10 million users across 180+ countries
Negative
- None.
Market reaction after Dream Bowl token trading launch: SCLX +3.33% in the Jul 6 session
In the Jul 6 session, SCLX gained 3.33%, reflecting a moderate positive market reaction. Argus tracked a peak move of +15.8% during that session. Argus tracked a trough of -24.6% from its starting point during tracking. Our momentum scanner triggered 37 alerts that day, indicating elevated trading interest and price volatility. Trading volume was exceptionally heavy at 25.1x the daily average, suggesting very strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 25 | Shareholder letter | Positive | +3.4% | Shareholder letter highlighting portfolio gains, Scilex repayments, and index inclusion. |
| Jun 16 | Token listing plan | Positive | -26.0% | Announcement of planned Dream Bowl token listing on Biconomy to provide liquidity. |
| May 20 | AI venture deals | Positive | +2.0% | Datavault AI and Wellgistics structuring DelivMeds AI via multiple transactions. |
| May 05 | Subsidiary sale deal | Positive | -3.8% | Agreement to sell ACEA Pharma for stock valued at $1,000,000,000 with majority stake retained. |
| May 04 | Token dividend setup | Positive | +5.4% | Board approval of Dream Bowl token dividend and intent to list tokens on Biconomy. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent newsflow shows both aligned and sharply contrary price reactions, particularly around Dream Bowl token announcements and strategic transactions.
Key Terms
meme coin financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
PALO ALTO, Calif., July 06, 2026 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today announced that the Dream Bowl I Meme Coin tokens (“Dream Bowl Tokens”) commence trading on the Biconomy Exchange on July 6, 2026.
To view the Dream Bowl Tokens now trading on the Biconomy Exchange, please click https://www.biconomy.com/exchange/DREAM1_USDT.
Scilex believes that the ability to trade the Dream Bowl Tokens may deliver liquidity and allow for broad distribution of such tokens for the stockholders and certain other eligible equityholders of Scilex (collectively, the “Participating Holders”) that received such tokens in prior distributions by the Company and by Datavault AI Inc (Nasdaq: DVLT). The Biconomy Exchange serves more than 10 million users and institutions across 180+ countries and consistently ranks among the top 40 global exchanges by trading volume, with average daily volume of approximately
For more information on Scilex Holding Company, refer to www.scilexholding.com
For more information on Semnur Pharmaceuticals, Inc., refer to www.semnurpharma.com
For more information on ZTlido® including Full Prescribing Information, refer to www.ztlido.com.
For more information on ELYXYB®, including Full Prescribing Information, refer to www.elyxyb.com.
For more information on Gloperba®, including Full Prescribing Information, refer to www.gloperba.com.
About Scilex Holding Company
Scilex is an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease. Scilex targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and is dedicated to advancing and improving patient outcomes. Scilex’s commercial products include: (i) ZTlido® (lidocaine topical system)
In addition, Scilex has three product candidates: (i) SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (“SEMDEXA” or “SP-102”), which is owned by Semnur Pharmaceuticals, Inc. (a majority owned subsidiary of Scilex) and is a novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica, for which Scilex has completed a Phase 3 study and was granted Fast Track status from the FDA in 2017; (ii) SP-103 (lidocaine topical system)
Scilex is headquartered in Palo Alto, California.
About Semnur Pharmaceuticals, Inc.
Semnur Pharmaceuticals, Inc. (“Semnur”) is a clinical late-stage specialty pharmaceutical company focused on the development and commercialization of novel non-opioid pain therapies. Semnur’s product candidate, SP-102 (SEMDEXA™), is the first non-opioid novel gel formulation administered epidurally in development for patients with moderate to severe chronic radicular pain/sciatica.
Semnur is headquartered in Palo Alto, California
Forward-Looking Statements
This press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts and may be accompanied by words that convey projected future events or outcomes, such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook” or variations of such words or by expressions of similar meaning. These forward-looking statements include, but are not limited to, statements regarding future events, including Scilex’s belief that the ability to trade the Dream Bowl Tokens on the Biconomy Exchange may deliver liquidity to the holders thereof and allow broad distribution of such tokens. These statements are based on management’s current expectations and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on, by any investor as a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Scilex. These statements are subject to a number of risks and uncertainties regarding Scilex’s business. These risks and uncertainties include, but are not limited to, general economic, political and business conditions; the ability of Scilex and its subsidiaries to develop and successfully market products; the ability of Scilex and its subsidiaries to grow and manage growth profitably and retain its key employees; the risk that the potential product candidates that Scilex develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all; risks relating to uncertainty regarding the regulatory pathway for Scilex’s product candidates; the risk that Scilex’s product candidates may not be beneficial to patients or successfully commercialized; the risk that Scilex has overestimated the size of the target patient population, their willingness to try new therapies and the willingness of physicians to prescribe these therapies; risks that the prior results of the clinical trials may not be replicated; regulatory and intellectual property risks; and other risks and uncertainties indicated from time to time and other risks set forth in Scilex’s filings with the SEC. There may be additional risks that Scilex presently does not know or that Scilex currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements provide Scilex’s expectations, plans or forecasts of future events and views as of the date of the communication. Scilex anticipates that subsequent events and developments will cause such assessments to change. However, while Scilex may elect to update these forward-looking statements at some point in the future, Scilex specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Scilex’s assessments as of any date subsequent to the date of this communication. Accordingly, investors are cautioned not to place undue reliance on these forward-looking statements.
Contacts:
Investors and Media
Scilex Holding Company
960 San Antonio Road
Palo Alto, CA 94303
Office: (650) 516-4310
Email: investorrelations@scilexholding.com
Website: www.scilexholding.com
SEMDEXA™ (SP-102) is a trademark owned by Semnur Pharmaceuticals, Inc., a majority-owned subsidiary of Scilex Holding Company. A proprietary name review by the FDA is planned.
ZTlido® is a registered trademark owned by Scilex Pharmaceuticals Inc., a wholly-owned subsidiary of Scilex Holding Company.
Gloperba® is the subject of an exclusive, transferable license to use the registered trademark by Scilex Holding Company.
ELYXYB® is a registered trademark owned by Scilex Holding Company.
Scilex Bio™ is a trademark owned by Scilex Holding Company.
All other trademarks are the property of their respective owners.
© 2026 Scilex Holding Company All Rights Reserved.
